Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
Robert L. Hoffman(Pfizer (United States)), Robert S. Kania(Pfizer (United States)), Mary A. Brothers(Pfizer (United States)), Jay F. Davies(Pfizer (United States)), Rose Ann Ferre(Pfizer (United States)), K.S. Gajiwala(Pfizer (United States)), Mingying He(Pfizer (United States)), Robert J. Hogan(Southern Research Institute), Kirk Kozminski(Pfizer (United States)), Lilian Y. Li(Pfizer (United States)), Jonathan W. Lockner(Pfizer (United States)), Jihong Lou(Pfizer (United States)), Michelle T. Marra(Pfizer (United States)), Lennert J. Mitchell(Pfizer (United States)), Brion W. Murray(Pfizer (United States)), James A. Nieman(Pfizer (United States)), Stephen Noell(Pfizer (United States)), Simon Planken(Pfizer (United States)), Thomas Rowe(Southern Research Institute), Kevin Ryan(Pfizer (United States)), George J. Smith(Pfizer (United States)), James Solowiej(Pfizer (United States)), Claire M. Steppan(Pfizer (United States)), Barbara Taggart(Southern Research Institute)
Cited by 530Open Access
Abstract
with suitable pharmaceutical properties to warrant further development as an intravenous treatment for COVID-19.
Related Papers
No related papers found
Powered by citation graph analysis